Pyxis Oncology (NASDAQ:PYXS) and Bicycle Therapeutics (NASDAQ:BCYC) Head to Head Review

Pyxis Oncology (NASDAQ:PYXS) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, earnings, profitability, risk and dividends.

Analyst Recommendations

This is a summary of recent ratings and target prices for Pyxis Oncology and Bicycle Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1	1	8	0	2.70
Bicycle Therapeutics	2	3	5	0	2.30

Pyxis Oncology presently has a consensus price target of $8.75, indicating a potential upside of 420.83%. Bicycle Therapeutics has a consensus price target of $13.86, indicating a potential upside of 290.34%. Given Pyxis Oncology’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Pyxis Oncology is more favorable than Bicycle Therapeutics.

Volatility & Risk

Pyxis Oncology has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500.

Profitability

This table compares Pyxis Oncology and Bicycle Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-215.23%	-112.19%
Bicycle Therapeutics	-311.11%	-33.22%	-27.79%

Valuation & Earnings

This table compares Pyxis Oncology and Bicycle Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86 million	10.11	-$79.62 million	($1.41)	-1.19
Bicycle Therapeutics	$72.86 million	3.41	-$218.96 million	($2.73)	-1.30

Pyxis Oncology has higher earnings, but lower revenue than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are held by institutional investors. 5.7% of Pyxis Oncology shares are held by company insiders. Comparatively, 22.0% of Bicycle Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Pyxis Oncology beats Bicycle Therapeutics on 7 of the 13 factors compared between the two stocks.

About Pyxis Oncology

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.